Can On­co­Host's PROphet pre­dict host re­sponse to can­cer treat­ments? In­vestors are wait­ing to find out

Last year, a small biotech out of Is­rael scored a mod­est $8 mil­lion in a Se­ries B to help fi­nance clin­i­cal tri­als and pre­pare for the up­com­ing launch of its main prod­uct, a ma­chine learn­ing-based di­ag­nos­tics plat­form. Re­cent­ly, the biotech went back for more — and got it.

On­co­Host an­nounced Tues­day morn­ing that it suc­cess­ful­ly raised $35 mil­lion in a Se­ries C fi­nanc­ing round led by Is­raeli healthtech VC ALIVE, with ad­di­tion­al in­vestors in­clud­ing the Se­ries B lead in­vestor, Our­Crowd. As to the com­pa­ny’s first goal, it is fo­cus­ing on the com­mer­cial launch of its plat­form named PROphet, which CEO Ofer Sharon told End­points News is slat­ed to launch some­time in Q3 this year — first­ly in the US.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN